COMPANY

Sling Therapeutics

HQ: Ann Arbor, MI source · slingtx.com ↗

Keywords: Graves ophthalmopathy Graves Orbitopathy Thyroid Eye Disease Endocrine System Diseases Eye Diseases Thyroid Associated Ophthalmopathy Thyroid Diseases Orbital Diseases Proptosis IGF1R Exophthalmos Hashimoto TED Thyroid Eye Disease Linsitinib

Location: Ann Arbor, MI · source · Oct 15, 2026

Profile checked Oct 10, 2026

$123.0MRaised (2 yrs)3Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $123M · announced Sep 16, 2026 Company release ↗
Source quote
- Sep 16, 2026 · Company release ↗
  “– Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the close of a $123 million Series C financing”

Raises announced in these releases: $123M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 16, 2026 Raise Private equity round — Series C: $123M (total, as published), announced Sep 16, 2026. Source: company's own press page. source ↗
Sep 16, 2026 Raise Series C · $123M source ↗
Aug 4, 2026 Trial start Phase 3: Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) source ↗
Oct 11, 2023 Trial start Phase 2/Phase 3: Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) source ↗
Jul 1, 2022 Trial start 2: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) source ↗

Upcoming milestones

Jun 30, 2028 (ESTIMATED) · Phase 3 · Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) · NCT07753603

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $123.0M. Last 2 years.

Sep 16, 2026 Private equity round — Series C: $123M (total, as published), announced Sep 16, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05276063	A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	2	Completed	Jul 1, 2022	Oct 15, 2024 (actual)
NCT07753603	Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)	Phase 3	Recruiting	Aug 4, 2026	Jun 30, 2028 (estimated)
NCT06112340	Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3	Recruiting	Oct 11, 2023	2026-06 (estimated)